Caplyta for Social Anxiety Disorder

This trial examines whether Caplyta (lumateperone) can reduce symptoms of Social Anxiety Disorder in adults. Participants will take either Caplyta or a placebo, which resembles the medication but contains no active ingredients, daily for eight weeks. The trial aims to determine if Caplyta can decrease the frequency and severity of social anxiety symptoms. It is best suited for adults diagnosed with Social Anxiety Disorder who have not responded to common medications. Participants must visit the clinic weekly for checkups and tests. As a Phase 4 trial, Caplyta has already received FDA approval and proven effective, and this research seeks to understand its benefits for more patients.

Yes, you may need to stop taking certain medications to join the trial. Specifically, you cannot take fluoxetine, MAO inhibitors, or other psychotropic medications within 14 to 28 days before starting the trial. However, if you are on a stable dose of a beta-blocker for hypertension, you can continue taking it.

Research has shown that Caplyta (lumateperone) is generally safe and well-tolerated, with studies finding no major safety issues. In clinical trials, participants taking lumateperone did not experience serious side effects, indicating its usual safety. However, medicines like Caplyta can increase the risk of death in elderly individuals with dementia-related psychosis, though this does not apply to this trial.

Unlike the standard treatments for social anxiety disorder, which typically include SSRIs or SNRIs like sertraline or venlafaxine, Caplyta (lumateperone) offers a unique approach. Caplyta works by modulating serotonin, dopamine, and glutamate neurotransmitter systems, potentially addressing symptoms more comprehensively. Researchers are excited because this novel mechanism might reduce the anxiety symptoms with fewer side effects associated with traditional medications. Additionally, Caplyta may be effective in a shorter time frame, offering quicker relief for individuals struggling with social anxiety.

This trial will compare Caplyta, also known as lumateperone, with a placebo for treating Social Anxiety Disorder. Studies have shown that Caplyta can significantly improve symptoms in conditions like major depressive disorder with anxious distress. For example, one study found that Caplyta reduced anxiety more than a placebo. Specifically, patients taking Caplyta had anxiety scores 3.2 points lower than those taking a placebo. Additionally, 40.1% of people using Caplyta responded well to the treatment, compared to only 25.3% of those on a placebo. These findings suggest that Caplyta may effectively reduce anxiety symptoms, offering promise for those considering it for Social Anxiety Disorder.¹³⁴⁵⁶